10x Genomics

Pleasanton, California, United States Life Sciences Public

10x Genomics is a leader in spatial biology and single-cell sequencing technologies, providing integrated instruments, consumables, and software for analyzing biological systems. The company develops the Xenium Analyzer platform for high-resolution spatial transcriptomics and RNA sequencing solutions (Chromium, Visium) for academic, government, biopharmaceutical, biotechnology, and research institutions globally.

Public Company

10x Genomics is publicly traded

IPO'd on September 12, 2019

TXG NASDAQ

This company is no longer available on our private secondary market. Shares can be traded publicly under TXG.

Overview

Company data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.

Founded

2012

Employees

1,100–1,250

Leadership

  • Serge Saxonov

    Co-Founder and Chief Executive Officer

    LinkedIn
  • Ben Hindson

    Co-Founder, Chief Scientific Officer, and President

  • Kevin Ness

    Co-Founder

  • Justin McAnear

    Chief Financial Officer

  • Michael Schnall-Levin

    Chief Technology Officer, Founding Scientist

  • Brad Crutchfield

    Chief Commercial Officer

Competitors

Competitor list is illustrative and may be incomplete, stale, or erroneous.

  • Illumina

    DNA sequencing and genomic analysis technology provider

  • Thermo Fisher Scientific

    Life sciences technology and genomics solutions provider

  • BGI Genomics

    Chinese genomics sequencing company

10x Genomics Investment FAQ

10x Genomics FAQ

Yes, 10x Genomics is publicly traded under the ticker symbol TXG on the NASDAQ. The company went public in September 12, 2019.

10x Genomics trades under the ticker symbol TXG on the NASDAQ. It began trading in September 12, 2019.

10x Genomics (TXG on the NASDAQ) shares can be purchased through any standard brokerage account — including Fidelity, Charles Schwab, TD Ameritrade, and online platforms like Robinhood or E*TRADE. Search for the ticker TXG to place an order.

10x Genomics went public in September 12, 2019 via ipo. 10x Genomics completed its IPO on September 12, 2019, pricing 9 million shares at $39 per share on the NASDAQ under ticker TXG. The stock surged 49% on first day of trading, opening at $54 and closing at $53.

10x Genomics was co-founded by Serge Saxonov, Ben Hindson, and Kevin Ness in 2012.

10x Genomics is headquartered in Pleasanton, California, United States.

Access live market data

Sign Up

Data collected with AI, which can make mistakes. Please double-check this information.